Just as Goldilocks sought porridge that was “just right,” St. Jude Children’s Research Hospital scientists reported that targeting “just right” levels of a mutant protein may offer a novel therapeutic approach to some cases of childhood leukemia. The findings appear today in the journal Nature Communications.
“The results suggest a new vulnerability that can be explored for treatment of about 10% of patients with B-cell acute lymphoblastic leukemia,” said corresponding author Jinghui Zhang, Ph.D., chair of the St. Jude Department of Computational Biology.
These B-ALL cases have a chromosomal rearrangement that creates a mutant gene. That gene fuses a segment of the IGH gene with part of the oncogene DUX4, CRLF2 or another gene.
The study provided the first detailed genomic and epigenomic map of the IGH-DUX4 rearrangement and discovered that the translocation occurs on the silenced copy of the IGH gene. Based on the findings, Zhang and her colleagues suggested the “Goldilocks principle” as a model for the IGH-DUX4 contribution to B-ALL. B-ALL accounts for about 80% of childhood ALL, making it the most common childhood cancer.
Zhang and other St. Jude researchers previously reported the association between pediatric ALL and the IGH-DUX4 chromosomal rearrangement. In this study, scientists used long-read, whole genome and transcription sequencing and other methods to provide a precise map of the complex genomic region where the translocation occurred. Long-read sequencing uses DNA segments that are about 10 times longer than more commonly used sequencing techniques.
The sequencing showed that the chromosome rearrangement puts DUX4 close to a DNA segment that normally functions as an enhancer of IGH expression.
DUX4 is a transcription factor that regulates gene expression. The protein is normally expressed early in embryonic development and not during development of B cells. But when researchers checked, they found DUX4 expression was much higher in B-ALL patients with the IGH-DUX4 rearrangement than during normal embryonic development.
Combining long-read sequencing with epigenetic and 3D genomic profiling at the IGH region, yielded a surprise. Researchers found that the IGH-DUX4 rearrangement was silenced on the IGH allele.
B cells and Goldilocks
IGH rearrangement is a normal part of B cell development and essential for antibody production. During the process, one copy of the IGH gene is randomly selected for expression. Expression of the other is epigenetically reduced by about 90%.
Researchers expected to find the fusion gene was selected for activation and expression. “When it comes to oncoproteins, the conventional wisdom is that more is often better for tumor cells,” Zhang said. “We found the opposite was true.”
Read the full text of the article:
Nature Communications. Published online: June 26, 2019
Co-author Tanja Gruber, M.D., Ph.D., of St. Jude Oncology, and her colleagues showed that adding DUX4 to mouse blood stem cells or to IGH-DUX4 B-ALL cells increased cell death via its suicide (apoptotic) pathway. The increase mirrored DUX4 levels. “The potential of DUX4 as a source of oncogenic stress may provide a unique angle for IGH-DUX4 treatment,” Gruber said.
The findings led researchers to propose a model of IGH-DUX4 B-ALL based on the Goldilocks principle. “Since too much DUX4 dooms cells and too little DUX4 prevents cells from transforming to tumor cells, moderate-level DUX4 expression on the silenced IGH allele may provide the selective advantage necessary to promote leukemia cells,” said first author Liqing Tian, Ph.D., a postdoctoral fellow in Zhang’s laboratory.
The other authors are Ying Shao, Stephanie Nance, Jinjun Dang, Beisi Xu, Xiaotu Ma, Yongjin Li, Bensheng Ju, Li Dong, Scott Newman, Xin Zhou, Patrick Schreiner, Chunliang Li and John Easton of St. Jude; and Elizabeth Tseng, Ting Hon and Meredith Ashby of Pacific Biosciences, Menlo Park, California.
The research was supported in part by grants (CA216391, CA021765) from the National Cancer Institute and the National Institutes of Health; and ALSAC, the fundraising and awareness organization of St. Jude.
St. Jude Children's Research Hospital
St. Jude Children's Research Hospital is leading the way the world understands, treats and cures childhood cancer and other life-threatening diseases. It is the only National Cancer Institute-designated Comprehensive Cancer Center devoted solely to children. Treatments developed at St. Jude have helped push the overall childhood cancer survival rate from 20% to 80% since the hospital opened more than 50 years ago. St. Jude freely shares the breakthroughs it makes, and every child saved at St. Jude means doctors and scientists worldwide can use that knowledge to save thousands more children. Families never receive a bill from St. Jude for treatment, travel, housing and food — because all a family should worry about is helping their child live. To learn more, visit stjude.org or follow St. Jude on social media at @stjuderesearch.
St. Jude Media Relations Contacts
Rae Lyn Rushing
Manager, Media Relations
Desk: (901) 595-4419
Cell: (901) 686-2597
Media Relations Strategist
(901) 595-0564 (Desk)
(256) 244-2048 (Cell)